Solar Foods (SFOODS) investor relations material

Executive summary

• Transitioned from technology innovator to commercial operations, securing first U.S. and Italy supply agreements, MoUs for 6,000 tonnes/year Solein commercialization, and expanding into health and performance nutrition markets.

• Launched Solein-powered products with partners in the U.S., Italy, Finland, and Japan, demonstrating strong B2B and consumer acceptance.

• Successfully scaled production technology 100-fold at Factory 01, validating industrial-scale parameters and supporting Factory 02 profitability.

• Initiated pre-engineering for Factory 02, with phased construction and potential for multiple facilities at one site to de-risk investment and meet demand.

• Management team restructured, including new CEO appointment, to support growth and accelerate go-to-market.

Financial highlights

• Operating loss for H1 2025 was EUR 4.8 million, up from EUR 4.4 million year-over-year; total loss for the period was EUR 5.4 million, improved from EUR 5.7 million.

• Cash and cash equivalents at period end were EUR 12.7 million, down from EUR 24.2 million year-over-year.

• Equity ratio at period end was 46%, down from 51% year-over-year; net gearing at 31%, up from -12%.

• Order book reached EUR 1.5 million, reflecting new supply agreements.

• Personnel increased to 57 from 40 year-over-year.

Outlook and guidance

• Factory 02's first phase targeted for production in 2028, aiming for 3.2 kilotons output and EUR 50 million revenue.

• Full strategy period (2025–2030) capital requirement estimated at EUR 100 million to EUR 200 million with partners, with modular factory expansion planned.

• Focus on securing sales agreements for Factory 01 and building order book for Factory 02, especially in the U.S. health and performance protein market.

• Factory 02 investment decision expected in 2026; first U.S. consumer products anticipated in H2 2025.

• No separate short-term financial guidance provided; existing financial targets maintained.